ZyVersa Therapeutics Inc. (ZVSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZyVersa Therapeutics Inc. (ZVSA) has a cash flow conversion efficiency ratio of 119.987x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.41 Billion) by net assets ($-11.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of ZyVersa Therapeutics Inc. to measure how many days the company can operate on defensive assets alone.
ZyVersa Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how ZyVersa Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ZyVersa Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZyVersa Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Assetowl Ltd
AU:AO1
|
0.066x |
|
Focusrite Plc
LSE:TUNE
|
0.145x |
|
Northgold AB
ST:NG
|
-0.044x |
|
Advent Technologies Holdings Inc
NASDAQ:ADN
|
-0.015x |
|
Tasfoods Ltd
AU:TFL
|
-0.576x |
|
Greenlite Ventures Inc.
NASDAQ:GRNLD
|
N/A |
|
Brave Bison Group PLC
LSE:BBSN
|
0.118x |
|
Elbit Med Tech
TA:EMTC
|
-0.005x |
Annual Cash Flow Conversion Efficiency for ZyVersa Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of ZyVersa Therapeutics Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see ZVSA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.52 Million | $-7.56 Million | -0.888x | -12.72% |
| 2023-12-31 | $11.07 Million | $-8.72 Million | -0.787x | -1510.74% |
| 2022-12-31 | $99.99 Million | $-4.89 Million | -0.049x | -112.04% |
| 2021-12-31 | $-12.50 Million | $-5.08 Million | 0.406x | -31.99% |
| 2020-12-31 | $-8.56 Million | $-5.11 Million | 0.597x | -- |
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more